SAN DIEGO, Oct. 18, 2017 /PRNewswire/ -- NuVasive, Inc.
(NASDAQ: NUVA), a leading medical device company focused on
transforming spine surgery with minimally disruptive,
procedurally-integrated solutions, today announced the launch of
Modulus® XLIF® titanium implants. The new 3D-printed, fully porous
device provides a differentiated offering for the Company's
flagship XLIF procedure, highlighting a continued commitment to
innovation in developing first-of-its-kind technology to support
its leading lateral spine procedure.
The new Modulus titanium implants are developed using additive
manufacturing technology, or 3D printing, to create an organic,
porous architecture that mimics the porosity and stiffness of bone
for reduced stress shielding. By employing advanced microporous
surface topography, Modulus XLIF creates an ideal environment for
bone in-growth1. The device's optimized architecture
also leads to improved imaging characteristics compared to
traditional titanium interbody devices.
"We've seen an increase in surgeon preference to use titanium
interbody options in spine surgeries, and we were confident we
could develop a titanium option that delivers the porous properties
surgeons need," said Matt Link,
executive vice president of strategy, technology and corporate
development of NuVasive. "Modulus XLIF maximizes the potential of
3D-printed spinal implants through the application of unique and
advanced software optimization processes. This product launch
further represents our continued commitment to advancing surgical
materials, and delivering best-in-class implants that provide
superior osseointegration and biomechanics."
Modulus XLIF's novel technology represents an advancement in the
growing titanium interbody market. The implant expands the
offerings used in the XLIF procedure, the only lateral approach
spine procedure proven with over 15 years of clinical evidence and
400 peer-reviewed lateral-approach, XLIF specific publications.
"Surface architecture is an increasingly important part of the
fusion process," said Kade Huntsman,
MD, orthopedic spine surgeon with the Salt Lake Orthopaedic Clinic
in Salt Lake City, Utah. "The
design of Modulus XLIF maximizes the potential of additive
manufacturing through the combination of highly porous endplates
with an optimized internal structure."
NuVasive will showcase its market-leading,
procedurally-integrated technologies, including the new Modulus
XLIF in NuVasive Booth #713 at the North American Spine Society
Annual Meeting held October 25-28,
2017 in Orlando, Fla.
About NuVasive
NuVasive,
Inc. (NASDAQ: NUVA) is transforming spine surgery and beyond with
minimally invasive, procedurally-integrated solutions designed to
deliver reproducible and clinically-proven surgical outcomes. The
Company's portfolio includes access instruments, implantable
hardware, biologics, software systems for surgical planning,
navigation and imaging solutions, magnetically adjustable implant
systems for spine and orthopedics, and intraoperative monitoring
service offerings. With $962 million
in revenues (2016), NuVasive has an approximate 2,300 person
workforce in more than 40 countries serving surgeons, hospitals and
patients. For more information, please visit www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions
you that statements included in this news release that are not a
description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which,
if they do not materialize or prove correct, could cause NuVasive's
results to differ materially from historical results or those
expressed or implied by such forward-looking statements. The
potential risks and uncertainties which contribute to the uncertain
nature of these statements include, among others, risks associated
with acceptance of the Company's surgical products and procedures
by spine surgeons, development and acceptance of new products or
product enhancements, clinical and statistical verification of the
benefits achieved via the use of NuVasive's products (including the
iGA™ platform), the Company's ability to effectually manage
inventory as it continues to release new products, its ability to
recruit and retain management and key personnel, and the other
risks and uncertainties described in NuVasive's news releases and
periodic filings with the Securities and Exchange Commission.
NuVasive's public filings with the Securities and Exchange
Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect
events or circumstances arising after the date on which it was
made.
1 Preclinical data on file.
Data may not be representative of clinical results.
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/nuvasive-launches-new-3d-printed-porous-titanium-implant-in-expanding-advanced-materials-science-portfolio-300539206.html
SOURCE NuVasive, Inc.